Genetic Inhibition of Mitochondrial Permeability Transition Pore Exacerbates Ryanodine Receptor 2 Dysfunction in Arrhythmic Disease
- PMID: 36672139
- PMCID: PMC9856515
- DOI: 10.3390/cells12020204
Genetic Inhibition of Mitochondrial Permeability Transition Pore Exacerbates Ryanodine Receptor 2 Dysfunction in Arrhythmic Disease
Abstract
The brief opening mode of the mitochondrial permeability transition pore (mPTP) serves as a calcium (Ca2+) release valve to prevent mitochondrial Ca2+ (mCa2+) overload. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a stress-induced arrhythmic syndrome due to mutations in the Ca2+ release channel complex of ryanodine receptor 2 (RyR2). We hypothesize that inhibiting the mPTP opening in CPVT exacerbates the disease phenotype. By crossbreeding a CPVT model of CASQ2 knockout (KO) with a mouse missing CypD, an activator of mPTP, a double KO model (DKO) was generated. Echocardiography, cardiac histology, and live-cell imaging were employed to assess the severity of cardiac pathology. Western blot and RNAseq were performed to evaluate the contribution of various signaling pathways. Although exacerbated arrhythmias were reported, the DKO model did not exhibit pathological remodeling. Myocyte Ca2+ handling was similar to that of the CASQ2 KO mouse at a low pacing frequency. However, increased ROS production, activation of the CaMKII pathway, and hyperphosphorylation of RyR2 were detected in DKO. Transcriptome analysis identified altered gene expression profiles associated with electrical instability in DKO. Our study provides evidence that genetic inhibition of mPTP exacerbates RyR2 dysfunction in CPVT by increasing activation of the CaMKII pathway and subsequent hyperphosphorylation of RyR2.
Keywords: CPVT; EC-coupling; calcium signaling; mitochondria.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9856515/bin/cells-12-00204-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9856515/bin/cells-12-00204-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9856515/bin/cells-12-00204-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9856515/bin/cells-12-00204-g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9856515/bin/cells-12-00204-g005.gif)
Similar articles
-
SR-Mitochondria Crosstalk Shapes Ca Signalling to Impact Pathophenotype in Disease Models Marked by Dysregulated Intracellular Ca Release.Cardiovasc Res. 2022 Oct 21;118(13):2819-2832. doi: 10.1093/cvr/cvab324. Cardiovasc Res. 2022. PMID: 34677619 Free PMC article.
-
Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.J Clin Invest. 2007 Jul;117(7):1814-23. doi: 10.1172/JCI31080. J Clin Invest. 2007. PMID: 17607358 Free PMC article.
-
Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.J Cardiovasc Electrophysiol. 2011 Mar;22(3):316-24. doi: 10.1111/j.1540-8167.2010.01877.x. Epub 2010 Aug 30. J Cardiovasc Electrophysiol. 2011. PMID: 20807279 Free PMC article.
-
Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.Curr Probl Cardiol. 2009 Jan;34(1):9-43. doi: 10.1016/j.cpcardiol.2008.09.002. Curr Probl Cardiol. 2009. PMID: 19068246 Review.
-
Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.Cardiovasc Res. 2005 Aug 15;67(3):379-87. doi: 10.1016/j.cardiores.2005.04.027. Cardiovasc Res. 2005. PMID: 15913575 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous